mRNAワクチン市場：技術タイプ別、投与経路別、製造プロセス別、ワクチン分類別、用途分野別、エンドユーザー別、流通チャネル別 - 2025年～2030年の世界予測

mRNAワクチン市場は、2024年には93億2,000万米ドルとなり、2025年には104億米ドル、CAGR 11.86%で成長し、2030年には182億8,000万米ドルに達すると予測されています。

mRNAワクチンは、現代のヘルスケアにおいて画期的な存在となっています。この革新的な治療カテゴリーは、特に近年、実験的技術から世界の予防接種の最前線へと急速に移行しています。mRNAワクチンの歩みは、数十年にわたる厳密な調査によって特徴づけられ、実験室での画期的な成果を救命のための臨床応用へと効果的に導いてきました。強力な免疫反応を引き起こすmRNAワクチンの能力は、合理化された開発スケジュールと相まって、出現しつつある病原体や慢性疾患との闘いにおけるmRNAワクチンの価値を際立たせています。

mRNAワクチン技術の出現は、従来のワクチン・プラットフォームを再定義するだけでなく、設計と製造に柔軟性をもたらします。この進化は個別化医療アプローチへの扉を開き、より幅広い感染症、遺伝性疾患、さらには腫瘍学的課題に対処する可能性を高めています。合成mRNA配列を活用することで、これらのワクチンは、新たな亜種や新種の病原体が発生した際に、より迅速に適応する道を開きます。科学界や産業界のリーダーたちは今、世界の公衆衛生のダイナミクスを変えつつあるこの分野において、生化学的な新知見と実用的な臨床応用の合流を目の当たりにしています。

この包括的なレビューでは、mRNAワクチン市場の基本的側面と戦略的意味合いについて掘り下げます。将来のヘルスケア開拓の舞台となる、深遠な技術革新、重要な市場セグメンテーション、地域および企業動向を探る。意思決定者がますます競合が激化し、ペースの速い環境を乗り切るには、これらの側面を理解することがmRNAワクチン技術の可能性を最大限に活用する鍵となります。

mRNAワクチンのエコシステムを再定義する変革的変化

mRNAワクチンの情勢は、科学的革新、規制状況の進化、そして国際保健分野における危機感の高まりによって、大きく変化しています。ヌクレオシド修飾と脂質ナノ粒子送達システムの改良における最近のブレークスルーは、mRNAプラットフォームの安全性と有効性を劇的に改善しました。これらの進歩は、創薬から市場投入までの道のりを加速させただけでなく、製薬業界の競合環境も再定義しました。

明確な規制当局のお墨付きと政府のイニシアティブは、こうした新規プラットフォームへの信頼をさらに高め、官民双方の投資急増につながっています。各国が将来のパンデミックへの備えを優先する中、mRNAワクチンの拡張性と適応性は魅力的な提案となっています。このようなダイナミックな動きは、学術界、産業界、規制機関の間の協力関係を促進し、革新的な治療法が出現する世界ヘルスの脅威に迅速に対応できる強固なエコシステムの基礎を築きつつあります。

本セクションでは、従来のワクチン戦略を方向転換させた、幾重にも重なる変化を探る。ラピッドプロトタイピング能力、臨床試験におけるデジタル統合、製造効率の向上が、どのように市場の舵取りを一括して行っているかに重点を置いています。こうしたシフトは、このセクターの回復力と、進化する世界ヘルスの需要に対応するための先端技術の統合能力を証明するものです。

業界動向を形成する主要セグメントに関する洞察

市場セグメンテーションでは、業界動向を形成する様々なセグメンテーション基準を検証することで、mRNAワクチン市場に対する微妙な理解が明らかになります。分析によると、技術志向のセグメンテーションが極めて重要であり、脂質ナノ粒子（LNP）システム、ネイキッドmRNA技術、ヌクレオシド修飾mRNAアプローチ、自己増幅mRNAプラットフォームなどのプラットフォームを通じて市場が調査されます。特に、ネイキッドmRNA技術のカテゴリーでは、ペプチドベースのキャリアとポリマーナノ粒子の特殊な使用を掘り下げており、効率性と標的送達の両方へのコミットメントを強調しています。

さらに、投与経路は市場力学に重要な洞察を与えます。吸入可能なmRNAワクチン、注射可能な製剤、経口デリバリーシステムの開発と差別化は、患者中心の治療への嗜好の進化と、非侵襲的なワクチン接種プロトコルへの推進を浮き彫りにしています。製造プロセスもまた、セグメンテーション戦略に大きく寄与しており、無細胞合成法と試験管内転写法の二分化に焦点を当てた研究が行われています。

ワクチンの分類は、予防用ワクチンと治療用ワクチンを区別することで、市場展望をさらに洗練させる。応用分野のレンズを通して見ると、市場は、心血管疾患、遺伝性疾患-嚢胞性線維症治療や鎌状赤血球病に対する革新的なアプローチの徹底的な探求、COVID-19やインフルエンザなどの感染症に対する包括的な戦略など-を含む多様な治療ニーズにまたがっており、がん領域も同様に有望な焦点となっています。さらに、エンドユーザーセグメンテーションでは、バイオテクノロジー企業、開発業務受託機関、製薬企業、研究機関の貢献について詳しく説明しています。最後に、流通チャネルのセグメンテーションでは、病院薬局と小売薬局の役割を検討し、これらのワクチンが最終消費者にどのように届くかを理解する上で、新たな洞察を加えています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症の蔓延と新たなウイルスの発生により、mRNAワクチンの需要が高まっています。
    • 動物衛生分野におけるmRNAワクチンの拡大は市場の可能性を秘めている
    • パンデミックへの備えに対する国民と政府の支援がmRNAワクチンの取り組みを前進させる
  • 抑制要因
    • 誤った情報によって、新しいワクチン技術に対する国民の懐疑心が、ワクチンの普及を妨げる可能性があります。
  • 機会
    • mRNAワクチンの利点と安全性を促進するための教育キャンペーンと官民パートナーシップの開発
    • mRNAワクチンの研究開発を推進するための政府と民間の資金
  • 課題
    • mRNAワクチン承認のための複雑な規制枠組みを理解する
• 市場セグメンテーション分析
  • 技術タイプ：mRNAを細胞に効果的に送達する能力を持つ脂質ナノ粒子プラットフォームの使用が増加
  • 流通チャネル：病院薬局での保管とタイムリーな投与の採用 mRNAワクチン
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 mRNAワクチン市場：技術タイプ別

• 脂質ナノ粒子（LNP）プラットフォーム
• ネイキッドmRNAテクノロジー
  • ペプチドベースのキャリア
  • ポリマーナノ粒子
• ヌクレオシド修飾mRNA技術
• 自己増幅mRNAプラットフォーム

第7章 mRNAワクチン市場：投与経路別

• 吸入mRNAワクチン
• 注入mRNAワクチン
• 経口投与システム

第8章 mRNAワクチン市場：製造プロセス別

• 無細胞合成
• In Vitro転写

第9章 mRNAワクチン市場：ワクチン分類別

• 予防ワクチン
• 治療ワクチン

第10章 mRNAワクチン市場：用途分野別

• 心血管疾患
• 遺伝性疾患
  • 嚢胞性線維症の治療
  • 鎌状赤血球症のmRNAアプローチ
• 感染症
  • COVID-19ワクチン
  • インフルエンザ mRNAワクチン
• 腫瘍学

第11章 mRNAワクチン市場：エンドユーザー別

• バイオテクノロジー企業
• 受託研究機関
• 製薬会社
• 研究機関

第12章 mRNAワクチン市場：流通チャネル別

• 病院薬局
• 小売薬局

第13章 南北アメリカのmRNAワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋地域のmRNAワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカのmRNAワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Acuitas Therapeutics Inc.
• Alnylam Pharmaceuticals, Inc.
• Arcturus Therapeutics Holdings Inc.
• AstraZeneca PLC
• Bavarian Nordic AS
• BioNTech SE
• Chongqing Zhifei Biological Products Co.,Ltd.
• CureVac N.V.
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Ethris GmbH
• GlaxoSmithKline PLC
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Moderna Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Sanofi S.A.
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. MRNA VACCINES MARKET MULTI-CURRENCY
• FIGURE 2. MRNA VACCINES MARKET MULTI-LANGUAGE
• FIGURE 3. MRNA VACCINES MARKET RESEARCH PROCESS
• FIGURE 4. MRNA VACCINES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL MRNA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 21. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 25. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 29. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 30. MRNA VACCINES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 31. MRNA VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. MRNA VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL MRNA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MRNA VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MRNA VACCINES MARKET SIZE, BY LIPID NANOPARTICLE (LNP) PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MRNA VACCINES MARKET SIZE, BY PEPTIDE-BASED CARRIERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MRNA VACCINES MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MRNA VACCINES MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MRNA VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MRNA VACCINES MARKET SIZE, BY INHALABLE MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MRNA VACCINES MARKET SIZE, BY INJECTABLE MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MRNA VACCINES MARKET SIZE, BY ORAL DELIVERY SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MRNA VACCINES MARKET SIZE, BY CELL-FREE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MRNA VACCINES MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MRNA VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MRNA VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MRNA VACCINES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL MRNA VACCINES MARKET SIZE, BY CYSTIC FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL MRNA VACCINES MARKET SIZE, BY SICKLE CELL DISEASE MRNA APPROACHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL MRNA VACCINES MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL MRNA VACCINES MARKET SIZE, BY INFLUENZA MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL MRNA VACCINES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL MRNA VACCINES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL MRNA VACCINES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL MRNA VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL MRNA VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL MRNA VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL MRNA VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. CANADA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. CANADA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 77. CANADA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. CANADA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 79. CANADA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 81. CANADA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 82. CANADA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. CANADA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. CANADA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. CHINA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. CHINA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 129. CHINA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. CHINA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 131. CHINA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 132. CHINA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 133. CHINA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 134. CHINA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 135. CHINA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. CHINA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. INDIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. INDIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 139. INDIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. INDIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 141. INDIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 142. INDIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 143. INDIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 144. INDIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 145. INDIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. INDIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. MALAYSIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. PHILIPPINES MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. SINGAPORE MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. TAIWAN MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 217. THAILAND MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. VIETNAM MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 248. DENMARK MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 249. DENMARK MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 258. EGYPT MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. EGYPT MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 268. FINLAND MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 269. FINLAND MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. FRANCE MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 279. FRANCE MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 288. GERMANY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 289. GERMANY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 298. ISRAEL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 299. ISRAEL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 308. ITALY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 309. ITALY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 310. ITALY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 311. ITALY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 312. ITALY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 313. ITALY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 314. ITALY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 315. ITALY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 316. ITALY MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 317. ITALY MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 318. NETHERLANDS MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 319. NETHERLANDS MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 320. NETHERLANDS MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 321. NETHERLANDS MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 322. NETHERLANDS MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 323. NETHERLANDS MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 324. NETHERLANDS MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 325. NETHERLANDS MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 326. NETHERLANDS MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 327. NETHERLANDS MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 328. NIGERIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 329. NIGERIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 330. NIGERIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 331. NIGERIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 332. NIGERIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 333. NIGERIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 334. NIGERIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 335. NIGERIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 336. NIGERIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 337. NIGERIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 338. NORWAY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 339. NORWAY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 340. NORWAY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 341. NORWAY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 342. NORWAY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
• TABLE 343. NORWAY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
• TABLE 344. NORWAY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 345. NORWAY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
• TABLE 346. NORWAY MRNA VACCINES MARKET SIZ

The mRNA Vaccines Market was valued at USD 9.32 billion in 2024 and is projected to grow to USD 10.40 billion in 2025, with a CAGR of 11.86%, reaching USD 18.28 billion by 2030.

mRNA vaccines have emerged as a groundbreaking force within modern healthcare. This innovative therapeutic category has rapidly transitioned from experimental technology to the forefront of global immunization efforts, especially in recent years. The journey of mRNA vaccines is characterized by decades of rigorous research that has effectively translated laboratory breakthroughs into life-saving clinical applications. Their ability to elicit robust immune responses combined with a streamlined development timeline underscores their value in combating both emergent pathogens and chronic diseases.

The advent of mRNA vaccine technology not only redefines traditional vaccine platforms but also introduces a level of flexibility in design and manufacturing. This evolution has opened doors to personalized medical approaches, increasing the potential to address a wider array of infectious diseases, genetic disorders, and even oncological challenges. By leveraging synthetic mRNA sequences, these vaccines pave the way for quicker adaptations when new variants or novel pathogens arise. The scientific community and industry leaders are now witnessing the confluence of novel biochemical insights and practical clinical applications in a field that is transforming global public health dynamics.

In this comprehensive review, we delve into the fundamental aspects and strategic implications of the mRNA vaccine market. The discussion will explore the profound technological innovations, critical market segmentations, and regional as well as corporate trends that are setting the stage for future healthcare developments. As decision-makers navigate an increasingly competitive and fast-paced environment, understanding these dimensions is key to leveraging the full potential of mRNA vaccine technology.

Transformative Shifts Redefining the mRNA Vaccine Ecosystem

The landscape of mRNA vaccines has experienced transformative shifts driven by scientific innovation, regulatory evolution, and a heightened sense of urgency within the global health arena. Recent breakthroughs in nucleoside modification and the refinement of lipid nanoparticle delivery systems have dramatically improved the safety and efficacy of mRNA platforms. These advancements have not only accelerated the pathway from discovery to market but also redefined the competitive environment in the pharmaceutical industry.

Clear regulatory endorsements and government initiatives have further bolstered confidence in these novel platforms, leading to a surge in both public and private investment. As nations prioritize preparedness against future pandemics, the scalable and adaptive nature of mRNA vaccines becomes an attractive proposition. This dynamic is fostering collaboration among academia, industry, and regulatory bodies, laying the groundwork for a robust ecosystem where innovative therapies can quickly respond to emergent global health threats.

This section explores the multiple layers of change that have reoriented traditional vaccine strategies. Emphasis is placed on how rapid prototyping capabilities, digital integration in clinical trials, and enhanced manufacturing efficiencies are collectively steering the market. These shifts are a testament to the sector's resilience and its ability to integrate advanced technologies to meet evolving global health demands.

Key Segmentation Insights Shaping Industry Trends

A nuanced understanding of the mRNA vaccine market is evident when one examines the varied segmentation criteria that frame industry trends. The analysis reveals that technology-oriented segmentation is pivotal, where the market is examined through platforms such as lipid nanoparticle (LNP) systems, naked mRNA technologies, nucleoside-modified mRNA approaches, and self-amplifying mRNA platforms. Specifically, the category of naked mRNA technologies delves deeper into the specialized use of peptide-based carriers and polymeric nanoparticles, underscoring a commitment to both efficiency and targeted delivery.

Additionally, the route of administration provides critical insights into market dynamics. The development and differentiation among inhalable mRNA vaccines, injectable formulations, and oral delivery systems highlight the evolving preferences for patient-centric treatments and the drive towards non-invasive vaccination protocols. Manufacturing processes also contribute significantly to the segmentation strategy, with studies focusing on the dichotomy between cell-free synthesis and in vitro transcription methods, each presenting distinct advantages in terms of scalability and cost-effectiveness.

Vaccine classification further refines market perspectives by distinguishing between preventive and therapeutic vaccines. When viewed through the lens of application areas, the market spans a diverse range of therapeutic needs including cardiovascular disorders, genetic diseases-with in-depth explorations into cystic fibrosis treatments and innovative approaches towards sickle cell disease-and comprehensive strategies against infectious diseases like COVID-19 and influenza; oncology remains an equally promising focus. Furthermore, end-user segmentation elaborates on the contributions of biotechnology firms, contract research organizations, pharmaceutical companies, and research institutes. Lastly, the distribution channel segmentation, examining the roles of both hospital pharmacies and retail pharmacies, adds another layer of insight in understanding how these vaccines reach the end consumer.

Based on Technology Type, market is studied across Lipid Nanoparticle (LNP) Platforms, Naked mRNA Technologies, Nucleoside-Modified mRNA Technologies, and Self-Amplifying mRNA Platforms. The Naked mRNA Technologies is further studied across Peptide-Based Carriers and Polymeric Nanoparticles.

Based on Route of Administration, market is studied across Inhalable mRNA Vaccines, Injectable mRNA Vaccines, and Oral Delivery System.

Based on Manufacturing Process, market is studied across Cell-Free Synthesis and In Vitro Transcription.

Based on Vaccine Classification, market is studied across Preventive Vaccines and Therapeutic Vaccines.

Based on Application Areas, market is studied across Cardiovascular Disorders, Genetic Disorders, Infectious Diseases, and Oncology. The Genetic Disorders is further studied across Cystic Fibrosis Treatments and Sickle Cell Disease mRNA Approaches. The Infectious Diseases is further studied across COVID-19 Vaccines and Influenza mRNA Vaccines.

Based on End-User, market is studied across Biotechnology Firms, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes.

Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.

Key Regional Dynamics Impacting Market Growth

Regional insights play a crucial role in understanding the geographical influences on the mRNA vaccine market. In the Americas, the landscape is characterized by strong research foundations and a robust network of partnerships, setting the stage for iterative innovation and dynamic market expansions. The mature healthcare infrastructure supports rapid adoption of mRNA vaccine solutions, ensuring that advancements translate effectively into public health outcomes.

The region encompassing Europe, the Middle East, and Africa is marked by a blend of sophisticated regulatory frameworks and dynamic market reforms. This diversity presents unique challenges and opportunities that stimulate investment in localized manufacturing and tailored vaccine formulations. Collaborations between academic institutions and industry stakeholders are particularly significant here, as they foster environments conducive to innovation and strategic market penetration.

In Asia-Pacific, rapid economic growth combined with increasing healthcare investments is catalyzing the adoption of advanced therapeutic solutions. The region demonstrates both flexibility in digital integration and a forward-thinking approach towards novel drug development. The strong emphasis on clinical research and expedited pathways for regulatory approvals is contributing to an ecosystem that is both agile and receptive to transformative therapies. Together, these regional dynamics illustrate a global market where local advancements fuel worldwide progress in mRNA vaccine technology.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Market Movers: Key Company Insights Driving Innovation

The competitive landscape of the mRNA vaccine market is shaped by a consortium of influential companies that are driving both innovation and strategic collaborations. Leading industry players such as Acuitas Therapeutics Inc. and Alnylam Pharmaceuticals, Inc. are at the cutting edge of vaccine delivery system advancements, while Arcturus Therapeutics Holdings Inc. continues to push boundaries with self-amplifying mRNA platforms. AstraZeneca PLC and Bavarian Nordic AS bring substantial resources to the table, ensuring that large-scale production and rapid distribution are seamlessly integrated into market strategies.

Companies like BioNTech SE and CureVac N.V. have significantly advanced the field through pioneering research and agile clinical development pathways. Chongqing Zhifei Biological Products Co.,Ltd. marks another key contributor by leveraging regional expertise to customize vaccine solutions for emerging markets. Furthermore, established pharmaceutical giants including Daiichi Sankyo Company, Limited, Eli Lilly and Company, Ethris GmbH, and GlaxoSmithKline PLC have expanded their interest in mRNA technology, integrating it within broader drug portfolios to respond to a spectrum of therapeutic needs.

Innovators such as Inovio Pharmaceuticals, Inc. and Johnson & Johnson Services, Inc. are complementing these efforts by focusing on fine-tuning delivery mechanisms and clinical efficacy. Meanwhile, Merck & Co., Inc. and Moderna Inc. have cemented their positions as trailblazers with substantial R&D investments and global partnerships. Not to be overlooked, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, and Sanofi S.A. continue to significantly influence market direction through strategic mergers and extensive clinical trials. Companies like Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated are also pivotal, contributing diversified expertise that enriches the competitive landscape and fosters a spirit of relentless innovation.

The report delves into recent significant developments in the mRNA Vaccines Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc., AstraZeneca PLC, Bavarian Nordic AS, BioNTech SE, Chongqing Zhifei Biological Products Co.,Ltd., CureVac N.V., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Ethris GmbH, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated. Strategic Recommendations for Industry Stakeholders

Industry stakeholders are encouraged to foster cross-disciplinary collaborations aimed at accelerating technological maturation and expanding market reach. Investment in research and development should be prioritized, with a keen focus on optimizing delivery systems and enhancing the scalability of manufacturing processes. Stakeholders must also adopt data-driven decision-making frameworks that leverage real-time analytics to forecast market trends and adapt to shifting regulatory environments.

A proactive approach in forming strategic alliances with academic research centers and technology innovators can create synergies that drive both clinical success and market penetration. Emphasis on embracing digital transformation, particularly in clinical trial management and patient engagement strategies, is essential for maintaining competitive advantage. By positioning themselves at the nexus of innovation and patient care, industry leaders can ensure their strategies remain both flexible and forward-thinking in an era marked by rapid change.

Conclusion: Reflecting on the mRNA Vaccine Market's Future Prospects

In summary, the mRNA vaccine market is positioned at a pivotal juncture, where technological breakthroughs and strategic global collaborations are converging to redefine healthcare solutions. The evolution from traditional vaccine platforms to advanced mRNA technologies illustrates a market driven by innovation, adaptability, and a relentless pursuit of precision medicine.

The synthesis of diverse segmentation insights not only unveils detailed market nuances but also highlights the critical role that regional dynamics and key corporate players play in shaping the industry. As the market continues to expand, the alignment of technological innovation with regulatory and commercial strategies will be instrumental in determining long-term success and global impact.

Ultimately, the future of mRNA vaccines is bright, with extensive opportunities emerging for growth, enhanced public health outcomes, and the democratization of advanced therapeutic solutions across diverse populations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of infectious diseases and emerging viral outbreaks spur demand for mRNA vaccines
    • 5.1.1.2. Expansion of mRNA vaccine in animal health sectors is set to market potential
    • 5.1.1.3. Public and governmental support for pandemic preparedness pushes forward mRNA vaccine initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. Public skepticism towards new vaccine technologies, by misinformation, could impede uptake.
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing educational campaigns and public-private partnerships to promote mRNA vaccine benefits and safety
    • 5.1.3.2. Governmental and private funding to advance mRNA vaccine research and development
  • 5.1.4. Challenges
    • 5.1.4.1. Understanding the complex regulatory frameworks for mRNA vaccine approvals
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology Type: Growing use of lipid nanoparticle platforms for their ability to deliver mRNA into cells effectively
  • 5.2.2. Distribution Channel: Adoption of hospital pharmacies for storing and timely administering mRNA vaccines
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. mRNA Vaccines Market, by Technology Type

• 6.1. Introduction
• 6.2. Lipid Nanoparticle (LNP) Platforms
• 6.3. Naked mRNA Technologies
  • 6.3.1. Peptide-Based Carriers
  • 6.3.2. Polymeric Nanoparticles
• 6.4. Nucleoside-Modified mRNA Technologies
• 6.5. Self-Amplifying mRNA Platforms

7. mRNA Vaccines Market, by Route of Administration

• 7.1. Introduction
• 7.2. Inhalable mRNA Vaccines
• 7.3. Injectable mRNA Vaccines
• 7.4. Oral Delivery System

8. mRNA Vaccines Market, by Manufacturing Process

• 8.1. Introduction
• 8.2. Cell-Free Synthesis
• 8.3. In Vitro Transcription

9. mRNA Vaccines Market, by Vaccine Classification

• 9.1. Introduction
• 9.2. Preventive Vaccines
• 9.3. Therapeutic Vaccines

10. mRNA Vaccines Market, by Application Areas

• 10.1. Introduction
• 10.2. Cardiovascular Disorders
• 10.3. Genetic Disorders
  • 10.3.1. Cystic Fibrosis Treatments
  • 10.3.2. Sickle Cell Disease mRNA Approaches
• 10.4. Infectious Diseases
  • 10.4.1. COVID-19 Vaccines
  • 10.4.2. Influenza mRNA Vaccines
• 10.5. Oncology

11. mRNA Vaccines Market, by End-User

• 11.1. Introduction
• 11.2. Biotechnology Firms
• 11.3. Contract Research Organizations
• 11.4. Pharmaceutical Companies
• 11.5. Research Institutes

12. mRNA Vaccines Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Retail Pharmacies

13. Americas mRNA Vaccines Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific mRNA Vaccines Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa mRNA Vaccines Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Pfizer and BioNTech secure FDA approval for tailored Omicron KP.2 COVID-19 vaccine
  • 16.3.2. BioNTech and CEPI joined hands to enhance Africa's mRNA vaccine landscape with innovative research and local manufacturing
  • 16.3.3. Moderna revealed late-stage trial advancements with progress in the evolution of mRNA vaccine technology
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Acuitas Therapeutics Inc.
• 2. Alnylam Pharmaceuticals, Inc.
• 3. Arcturus Therapeutics Holdings Inc.
• 4. AstraZeneca PLC
• 5. Bavarian Nordic AS
• 6. BioNTech SE
• 7. Chongqing Zhifei Biological Products Co.,Ltd.
• 8. CureVac N.V.
• 9. Daiichi Sankyo Company, Limited
• 10. Eli Lilly and Company
• 11. Ethris GmbH
• 12. GlaxoSmithKline PLC
• 13. Inovio Pharmaceuticals, Inc.
• 14. Johnson & Johnson Services, Inc.
• 15. Merck & Co., Inc.
• 16. Moderna Inc.
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Regeneron Pharmaceuticals, Inc.
• 20. Roche Holding AG
• 21. Sanofi S.A.
• 22. Sinovac Biotech Ltd.
• 23. Takeda Pharmaceutical Company Limited
• 24. Thermo Fisher Scientific Inc.
• 25. Vertex Pharmaceuticals Incorporated